Table 3 Summative assessment of factors shown to positively or negatively impact INR stability
Factor | Data source | Significant factors the impact INR stability |
|---|---|---|
Poorer INR Stability | ||
VKA Use in Community Setting vs. Anticoagulation Clinic | Meta-Regression | ↓ TTR by 7.1 to 7.2 % |
VKA Naïve vs. VKA-Experienced | Meta-Regression | ↓ TTR by 5.3 % |
Heart Failure | Multivariate Analysis | OR 1.41 for TTR Instability |
Diabetes Mellitus | Multivariate Analysis | OR 1.28 for TTR Instability |
Stroke History | Multivariate Analysis | OR 1.15 for TTR Instability |
Higher CHADS2 Score | Multivariate Analysis | ↓ TTR by 7.6 % (SAMe-TT2R2) |
Female Gender | Multivariate Analysis | ↓ TTR by 6.0 % (SAMe-TT2R2) |
Younger Age | Multivariate Analysis | ↓ TTR by 20.3 % Age <50 (SAMe-TT2R2) |
↓ TTR by 7.7 % Age 50–60 (SAMe-TT2R2) | ||
Minority Status | Multivariate Analysis | ↓ TTR by 18.5 % (SAMe-TT2R2) |
Smoking | Multivariate Analysis | ↓ TTR by 10.8 % (SAMe-TT2R2) |
Amiodarone Use | Multivariate Analysis | ↓ TTR by 7.7 % (SAMe-TT2R2) |
Better INR Stability | ||
VKA Self Management vs. No Self Management | Meta-Regression | ↑ TTR by 7.0 % |
European/United Kingdom Treatment vs. Elsewhere | Meta-Regression | ↑ TTR by 9.7 % |
Non-Warfarin VKAs vs. Warfarin | Meta-Regression | ↑ TTR by 9.2 % |
Male Gender | Multivariate Analysis | OR 0.78 for TTR Instability |
Hypertension | Multivariate Analysis | OR 0.86 for TTR Instability |
Beta-Blocker Use | Multivariate Analysis | ↑TTR by 4.8 % (SAMe-TT2R2) |
Verapamil Use | Multivariate Analysis | ↑ TTR by 6.3 % (SAMe-TT2R2) |